{'fraction_non_alphanumeric': 0.022058823529411766, 'fraction_numerical': 0.003676470588235294, 'mean_word_length': 5.8125, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Tackling liver cancer by a novel combination between OSU‐2S and sorafenib

Sorafenib is an FDA‐approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, the low efficacy and adverse effects at high doses limit the clinical application of sorafenib and strongly recommend its combination with other agents aiming at ameliorating its drawbacks. OSU‐2S, a PKCδ activator, was selected as a potential candidate anticancer agent to be combined with sorafenib to promote the anti‐cancer activity through synergistic interaction.